{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:58:11Z","timestamp":1790913491856,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":153,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101278","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:53:07Z","timestamp":1781535187000},"page":"101278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validation"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-7145","authenticated-orcid":false,"given":"Ki Hong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo Sang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Auck","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Hoon","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youn Soo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101278_bib0001","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012390","article-title":"Recent global trends in testicular cancer incidence and mortality","volume":"97","author":"Park","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.ctarc.2026.101278_bib0002","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/cancers16020428","article-title":"The immune landscape and immunotherapeutic strategies in platinum-refractory testicular germ cell tumors","volume":"16","author":"Evmorfopoulos","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2026.101278_bib0003","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/cncr.26375","article-title":"Progression-free and overall survival in patients with relapsed\/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design","volume":"118","author":"Feldman","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2026.101278_bib0004","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41416-024-02669-9","article-title":"T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets","volume":"130","author":"Islam","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101278_bib0005","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/andr.13751","article-title":"Unwrapping the immunological alterations in testicular germ cell tumors: from immune homeostasis to malignancy and emerging immunotherapies","volume":"13","author":"Farahani","year":"2025","journal-title":"Andrology"},{"key":"10.1016\/j.ctarc.2026.101278_bib0006","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.21037\/tau-2025-514","article-title":"Tumor mutational burden, gene expression patterns, and immune-cell deconvolution in testicular germ cell tumors","volume":"14","author":"Wang","year":"2025","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.ctarc.2026.101278_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/andr.70200","article-title":"T cell microenvironmental impacts and therapeutic opportunities: application to Human testicular germ cell tumors","author":"Islam","year":"2026","journal-title":"Andrology"},{"key":"10.1016\/j.ctarc.2026.101278_bib0008","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s10637-019-00805-4","article-title":"Phase II study of avelumab in multiple relapsed\/refractory germ cell cancer","volume":"37","author":"Mego","year":"2019","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ctarc.2026.101278_bib0009","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/annonc\/mdx680","article-title":"Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier cancer research network study GU14-206","volume":"29","author":"Adra","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101278_bib0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2018.09.010","article-title":"An open-label randomized phase 2 study of Durvalumab alone or in combination with Tremelimumab in patients with advanced germ cell tumors (APACHE): results from the first planned interim analysis","volume":"75","author":"Necchi","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ctarc.2026.101278_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2025.103169","article-title":"Advances in cell therapy for testicular cancer: a comprehensive overview of immunotherapy and stem cell therapy","volume":"98","author":"Mehr","year":"2026","journal-title":"Tissue Cell"},{"key":"10.1016\/j.ctarc.2026.101278_bib0012","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41422-020-0277-x","article-title":"The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity","volume":"30","author":"Schnell","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ctarc.2026.101278_bib0013","doi-asserted-by":"crossref","first-page":"20592","DOI":"10.18632\/oncotarget.4112","article-title":"Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer","volume":"6","author":"Xu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2026.101278_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/5524200","article-title":"Upregulated HAVCR2: a prognostic and immune-related marker in testicular germ cell tumors","volume":"2023","author":"Xue","year":"2023","journal-title":"Andrologia"},{"key":"10.1016\/j.ctarc.2026.101278_bib0015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41420-025-02802-4","article-title":"Single-cell analysis unravels divergent gene signatures shaping seminoma stemness and metastasis","volume":"11","author":"Bian","year":"2025","journal-title":"Cell Death. Discov."},{"key":"10.1016\/j.ctarc.2026.101278_bib0016","doi-asserted-by":"crossref","first-page":"31705","DOI":"10.18632\/oncotarget.15954","article-title":"TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2026.101278_bib0017","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4049\/jimmunol.0903275","article-title":"Tim-3\/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+ly-6G+ myeloid cells","volume":"185","author":"Dardalhon","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ctarc.2026.101278_bib0018","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.26938","article-title":"Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice","volume":"59","author":"Dolina","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ctarc.2026.101278_bib0019","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101278_bib0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdv574","article-title":"Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors","volume":"27","author":"Cierna","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101278_bib0021","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/bjc.2015.244","article-title":"Frequent PD-L1 expression in testicular germ cell tumors","volume":"113","author":"Fankhauser","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101278_bib0022","doi-asserted-by":"crossref","first-page":"21794","DOI":"10.18632\/oncotarget.15585","article-title":"Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors","volume":"8","author":"Chovanec","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2026.101278_bib0023","first-page":"1497","article-title":"Expression of the immune checkpoint receptor TIGIT in seminoma","volume":"18","author":"Hinsch","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ctarc.2026.101278_bib0024","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101278_bib0025","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3389\/fonc.2020.01288","article-title":"Prognostic values of TIM-3 expression in patients with solid tumors: a meta-analysis and database evaluation","volume":"10","author":"Qin","year":"2020","journal-title":"Front. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:52:31Z","timestamp":1790913151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"alternative-id":["S2468294226001899"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101278","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validation","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101278"}}